Medically reviewed
FDA Peptide Reclassification 2026: What You Need to Know
James MitchellMSc Biochemistry 4 min read
Overview
The FDA’s reclassification of peptides represents one of the most significant regulatory shifts in the peptide therapy landscape. Beginning in late 2024 and continuing through 2026, the FDA has been systematically categorising peptides used by compounding pharmacies into two distinct groups — Category 1 and Category 2 — with dramatically different implications for patient access.
This guide explains what the reclassification means, which peptides are affected, and how it impacts patients, clinics, and compounding pharmacies across the United States.
What Is the FDA Reclassification?
Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may compound medications — including peptides — that are not commercially available as FDA-approved drugs. However, the FDA maintains a list of substances that may or may not be used in compounding.
The reclassification process involves the FDA evaluating peptides and placing them into one of two categories:
Category 1: Nominated for Removal
Category 1 peptides are those the FDA has determined should not be used by compounding pharmacies. These peptides have been nominated for the “Difficult to Compound” or “Demonstrably Difficult to Compound” list, or have been flagged for safety concerns.
Compounding pharmacies that continue to produce Category 1 peptides may face enforcement action from the FDA.
Category 2: Under Evaluation
Category 2 peptides are those the FDA is still evaluating. While they remain under review, compounding pharmacies may generally continue to compound these peptides, though the regulatory landscape remains uncertain.
Many of the most popular peptides used in clinical practice — including BPC-157, TB-500, CJC-1295, and Ipamorelin — currently fall into Category 2.
Which Peptides Are Affected?
Notable Category 1 Peptides
- Several peptides previously available through compounding have been moved to Category 1
- The specific list is maintained by the FDA and updated periodically
- Compounding pharmacies have been given transition periods to phase out Category 1 peptides
Notable Category 2 Peptides
- BPC-157 — widely used for recovery and healing support
- TB-500 (Thymosin Beta-4) — tissue repair and recovery
- CJC-1295 — growth hormone releasing hormone analogue
- Ipamorelin — growth hormone secretagogue
- Thymosin Alpha-1 — immune modulation (notably, approved in 35+ countries outside the US)
Impact on Patients
Current Access
Patients currently receiving peptide therapy through prescribing physicians and compounding pharmacies may experience changes depending on the final classification of their peptides:
- Category 2 peptides: Generally still accessible through legitimate compounding pharmacies with a valid prescription
- Category 1 peptides: No longer available through compounding pharmacies
What Patients Should Do
- Consult your prescribing physician about how the reclassification may affect your current protocol
- Verify your pharmacy is a legitimate 503A or 503B compounding pharmacy
- Do not stockpile — this creates quality and safety risks
- Stay informed — regulatory changes may continue through 2026 and beyond
Impact on Clinics and Compounding Pharmacies
503A Pharmacies
Section 503A compounding pharmacies prepare medications based on individual patient prescriptions. These pharmacies:
- Must receive a patient-specific prescription before compounding
- Are regulated primarily at the state level
- Must follow USP standards for compounding
503B Outsourcing Facilities
Section 503B outsourcing facilities can compound medications without patient-specific prescriptions (for office use). These facilities:
- Are registered with and inspected by the FDA
- Must follow current Good Manufacturing Practices (cGMP)
- May be more heavily impacted by the reclassification
Timeline
| Date | Event |
|---|---|
| Late 2024 | FDA begins formal reclassification process |
| Early 2025 | Initial Category 1 and Category 2 designations published |
| Mid 2025 | Public comment periods for disputed classifications |
| 2026 | Ongoing evaluation of Category 2 peptides; enforcement of Category 1 restrictions |
| TBD | Final determination on remaining Category 2 peptides |
What This Means Going Forward
The reclassification reflects the FDA’s broader effort to increase oversight of the compounding industry, particularly for substances that are increasingly used off-label in clinical practice. Key points:
- The regulatory environment is evolving — classifications may change as the FDA completes its evaluation
- Legitimate clinical use continues — peptides that remain in Category 2 are still accessible through proper channels
- Quality matters more than ever — patients should ensure they are sourcing from reputable, licensed compounding pharmacies
- International context — some peptides banned or restricted in the US may be approved in other countries (Thymosin Alpha-1 is approved in 35+ nations)
Related Resources
- Are Peptides Legal? Multi-Market Guide
- Interactive Regulatory Tracker
- Provider Directory — find verified clinics offering peptide therapy
- 2026 Peptide Legality Guide — our comprehensive PDF guide